Evidence map›Paper›PMID 32879359›Full record

ArticleScientific reports2020

Targeted and redox-responsive drug delivery systems based on carbonic anhydrase IX-decorated mesoporous silica nanoparticles for cancer therapy.

Minmin Chen, Jinxia Hu, Lujing Wang, Yanru Li, Chenghao Zhu, Chen Chen, Ming Shi, Zhicheng Ju, Xichuan Cao, Zhuoqi Zhang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
4.7field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 86 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Minmin Chen *School of Materials and Physics, China University of Mining and Technology, Xuzhou, 221116, People's Republic of China.
Jinxia Hu *School of Materials and Physics, China University of Mining and Technology, Xuzhou, 221116, People's Republic of China.
Lujing WangSchool of Materials and Physics, China University of Mining and Technology, Xuzhou, 221116, People's Republic of China.
Yanru LiDepartment of Cardiology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, People's Republic of China.
Chenghao ZhuSchool of Materials and Physics, China University of Mining and Technology, Xuzhou, 221116, People's Republic of China.
Chen ChenSchool of Materials and Physics, China University of Mining and Technology, Xuzhou, 221116, People's Republic of China.
Ming ShiCancer Institute, Xuzhou Medical University, Xuzhou, 221002, People's Republic of China.
Zhicheng JuSchool of Materials and Physics, China University of Mining and Technology, Xuzhou, 221116, People's Republic of China.
Xichuan CaoSchool of Materials and Physics, China University of Mining and Technology, Xuzhou, 221116, People's Republic of China. xichuancao@cumt.edu.cn.
Zhuoqi ZhangDepartment of Cardiology, Affiliated Hospital of Xuzhou Medical University, Xuzhou, 221002, People's Republic of China. zhuoqizhang@sina.com.
China University of Mining and Technology · CNXuzhou Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In this work, we developed a new antibody-targeted and redox-responsive drug delivery system "MSNs-CAIX" by binding the anti-carbonic anhydrase IX antibody (A-CAIX Ab) on the surface of mesoporous silica nanoparticles (MSNs) via disulfide linkages. The design of the composite particles "MSNs-CAIX" involved the synthesis and surface functionalization with thiol groups, 2,2'-dipyridyl disulfide and CAIX antibody. In vitro, CAIX capping the doxorubicin hydrochloric (DOX)-loaded nanoparticles (DOX@MSNs-CAIX) exhibited effectively redox-responsive release in the presence of glutathione (GSH) owing to the cleavage of the disulfide bond. Compared with CAIX negative Mef cells (mouse embryo fibroblast), remarkably more DOX@MSNs-CAIX was internalized into CAIX positive 4T1 cells (mouse breast cancer cells) by receptor-mediation. Tumor targeting in vivo studies clearly demonstrated DOX@MSNs-CAIX accumulated in tumors and induced more tumor cells apoptosis in 4T1 tumor-bearing mice. With great potential, this drug delivery system is a promising candidate for targeted and redox-responsive cancer therapy.

Indexed as

Drug Delivery SystemsAnimalsAntibodies, Anti-IdiotypicApoptosisCarbonic Anhydrase IXDoxorubicinHeterograftsHumansImmunoconjugatesMetal NanoparticlesMiceNeoplasmsOxidation-ReductionPorositySilicon DioxideAntibodies, Anti-IdiotypicCarbonic Anhydrase IXDoxorubicinImmunoconjugatesSilicon Dioxide

Identifiers

PMID32879359
PMCPMC7467921
OpenAlexW3082806874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.